Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagrisso with SRS in EGFR+ NSCLC brain metastases
NCT03535363Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03535363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535363.